18889881171
Kalkine 0
countryflagUS

Bausch + Lomb Corp

Healthcare US BLCO

11.74USD
-0.02(0.17%)

Last update at 2025-05-19T18:51:00Z

Day Range

11.4611.79
LowHigh

52 Week Range

13.1621.69
LowHigh

Fundamentals

  • Previous Close 11.76
  • Market Cap7120.12M
  • Volume562527
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA635.00M
  • Revenue TTM4684.00M
  • Revenue Per Share TTM13.33
  • Gross Profit TTM 2249.00M
  • Diluted EPS TTM-1.04

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 73.00M 318.00M 290.00M 399.00M 417.00M
Minority interest 9.00M -11.00000M -1.00000M -5.00000M -9.00000M
Net income 15.00M 182.00M -17.00000M 298.00M 710.00M
Selling general administrative 1478.00M 1389.00M 1253.00M 1382.00M 1327.00M
Selling and marketing expenses - - - - -
Gross profit 2249.00M 2298.00M 2127.00M 2451.00M 2352.00M
Reconciled depreciation 379.00M 415.00M 442.00M 469.00M 495.00M
Ebit 207.00M 329.00M 260.00M 532.00M 437.00M
Ebitda 457.00M 785.00M 750.00M 1001.00M 932.00M
Depreciation and amortization 250.00M 456.00M 490.00M 469.00M 495.00M
Non operating income net other 12.00M - - - -
Operating income 207.00M 329.00M 260.00M 532.00M 416.00M
Other operating expenses 3548.00M 3419.00M 3114.00M 3315.00M 3238.00M
Interest expense 146.00M 63.00M 19.00M 138.00M 8.00M
Tax provision 58.00M 125.00M 307.00M 96.00M -302.00000M
Interest income 6.00M 0.00000M 3.00M 1.00M 0.00000M
Net interest income -140.00000M 0.00000M 3.00M 1.00M 0.00000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 58.00M 125.00M 307.00M 96.00M -302.00000M
Total revenue 3768.00M 3765.00M 3412.00M 3778.00M 3665.00M
Total operating expenses 2029.00M 1952.00M 1829.00M 1988.00M 1925.00M
Cost of revenue 1519.00M 1467.00M 1285.00M 1327.00M 1313.00M
Total other income expense net -134.00000M -11.00000M 30.00M -133.00000M -10.00000M
Discontinued operations - - - - -
Net income from continuing ops 15.00M 193.00M -17.00000M 303.00M 719.00M
Net income applicable to common shares 6.00M 182.00M -18.00000M 298.00M 710.00M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 13442.00M 11144.00M 10823.00M 11266.00M 11468.00M
Intangible assets 3589.00M 2058.00M 2264.00M 2562.00M 2855.00M
Earning assets - - - - -
Other current assets 541.00M 431.00M 165.00M 155.00M 198.00M
Total liab 6522.00M 4043.00M 1421.00M 1278.00M 1436.00M
Total stockholder equity 6850.00M 7033.00M 9329.00M 9918.00M 9959.00M
Deferred long term liab - 7.00M - - -
Other current liab 400.00M 901.00M 860.00M 731.00M 773.00M
Common stock - - 10364.00M 10807.00M 11005.00M
Capital stock 0.00000M 0.00000M 10364.00M 10807.00M 11005.00M
Retained earnings -254.00000M 6.00M - - -
Other liab - 244.00M 230.00M 286.00M 324.00M
Good will 4575.00M 4507.00M 4586.00M 4685.00M 4554.00M
Other assets - 1023.00M 1001.00M 1101.00M 1274.00M
Cash 331.00M 354.00M 174.00M 238.00M 192.00M
Cash and equivalents - - - - -
Total current liabilities 1579.00M 1296.00M 1099.00M 909.00M 1035.00M
Current deferred revenue 627.00M - - - -
Net debt 4231.00M 2082.00M -174.00000M -238.00000M -192.00000M
Short term debt 30.00M 25.00M - - -
Short long term debt 30.00M 25.00M - - -
Short long term debt total 4562.00M 2436.00M - - -
Other stockholder equity 8349.00M 8285.00M -1035.00000M -889.00000M -1046.00000M
Property plant equipment - 1300.00M 1337.00M 1264.00M 1090.00M
Total current assets 2742.00M 2137.00M 1635.00M 1654.00M 1695.00M
Long term investments - - - - -
Net tangible assets - 468.00M 2479.00M 2671.00M 2550.00M
Short term investments - - - - -
Net receivables 839.00M 724.00M 721.00M 645.00M 713.00M
Long term debt 4532.00M 2411.00M - - -
Inventory 1028.00M 628.00M 572.00M 616.00M 592.00M
Accounts payable 522.00M 370.00M 239.00M 178.00M 262.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - 68.00M - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -1245.00000M -1258.00000M -1035.00000M -889.00000M -1046.00000M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - 6.00M - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 206.00M 215.00M 180.00M 165.00M 175.00M
Deferred long term asset charges - - - - -
Non current assets total 10700.00M 9007.00M 9188.00M 9612.00M 9773.00M
Capital lease obligations - - - - -
Long term debt total - 2411.00M - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -40.00000M -5.00000M 3.00M -6.00000M -6.00000M
Change to liabilities 189.00M 163.00M -144.00000M 78.00M -19.00000M
Total cashflows from investing activities -215.00000M -214.00000M -256.00000M -186.00000M -74.00000M
Net borrowings 2424.00M 28.00M 28.00M 28.00M 28.00M
Total cash from financing activities 81.00M -712.00000M -232.00000M -606.00000M -665.00000M
Change to operating activities -7.00000M -13.00000M 40.00M -6.00000M -43.00000M
Net income 15.00M 193.00M -17.00000M 303.00M 719.00M
Change in cash 203.00M -61.00000M 46.00M 4.00M 16.00M
Begin period cash flow 177.00M 238.00M 192.00M 188.00M 172.00M
End period cash flow 380.00M 177.00M 238.00M 192.00M 188.00M
Total cash from operating activities 345.00M 873.00M 522.00M 799.00M 763.00M
Issuance of capital stock - - - - -
Depreciation 379.00M 415.00M 442.00M 469.00M 495.00M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory -106.00000M -15.00000M -32.00000M -91.00000M -7.00000M
Change to account receivables -95.00000M -107.00000M 77.00M -21.00000M -9.00000M
Sale purchase of stock -11.00000M - - - -
Other cashflows from financing activities 94.00M -712.00000M -232.00000M -606.00000M -665.00000M
Change to netincome -57.00000M 248.00M 157.00M 72.00M -364.00000M
Capital expenditures 175.00M 209.00M 259.00M 180.00M 101.00M
Change receivables -95.00000M - - - -
Cash flows other operating 12.00M - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes 211.00M - - - -
Change in working capital -19.00000M 28.00M -59.00000M -40.00000M -78.00000M
Stock based compensation 62.00M 62.00M 50.00M 50.00M 43.00M
Other non cash items -2.00000M 59.00M 9.00M 56.00M 28.00M
Free cash flow 170.00M 664.00M 263.00M 619.00M 662.00M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BLCO
Bausch + Lomb Corp		 -0.02 0.17% 11.74 - 17.18 1.52 1.07 2.44 20.23
ISRG
Intuitive Surgical Inc		 -2.795 0.50% 560.80 73.05 61.73 19.15 10.25 18.41 59.92
ESLOY
Essilor International SA		 0.94 0.64% 146.88 35.39 24.81 3.63 2.20 4.00 16.25
ESLOF
EssilorLuxottica Société anonyme		 2.14 0.73% 296.00 35.71 25.13 3.62 2.23 4.00 16.25
BDX
Becton Dickinson and Company		 0.96 0.55% 176.37 37.72 15.92 3.25 2.49 4.08 17.10

Reports Covered

Stock Research & News

View All

Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

Bausch + Lomb Corp

520 Applewood Crescent, Vaughan, ON, Canada, L4K 4B4

Key Executives

Name Title Year Born
Mr. Joseph C. Papa CEO & Director 1956
Mr. Osama A. Eldessouky Exec. VP & CFO 1972
Ms. Christina M. Ackermann Exec. VP, Gen. Counsel & Pres of Ophthalmic Pharmaceuticals 1965
Mr. Joseph F. Gordon Pres of Global Consumer, Surgical & Vision Care 1965
Ms. Kelly Webber Exec. VP & Chief HR Officer NA
Dr. Yehia Hashad M.D. Exec. VP of R&D and Chief Medical officer 1967
Mr. Louis W. Yu Exec. VP & Chief Quality Officer 1950
Mr. Dennis Asharin Exec. VP and Chief Global Manufacturing & Supply Chain Officer NA
Mr. Osama A. Eldessouky Executive VP & CFO 1972
Dr. Yehia Hashad M.D. Executive VP of Research & Development and Chief Medical officer 1967

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.